Timothy D Warner

List of Publications by Year in Descending Order

248 papers	14,538 citations	55 h-index	115 g-index
268 ext. papers	15,522 ext. citations	8.3 avg, IF	6.13 L-index

#	Paper	IF	Citations
248	Neutrophil-Derived Protein S100A8/A9 Alters the Platelet Proteome in Acute Myocardial Infarction and Is Associated With Changes in Platelet Reactivity. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, ATVBAHA121317113	9.4	2
247	Identification of a homozygous recessive variant in resulting in a congenital aspirin-like defect in platelet function. *Haematologica*, **2021**, 106, 1423-1432	6.6	6
246	Cyclooxygenases and the cardiovascular system. *Pharmacology & Therapeutics*, **2021**, 217, 107624	13.9	10
245	Proteome and functional decline as platelets age in the circulation. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 3095-3112	15.4	5
244	Platelet inhibition by P2Y antagonists is potentiated by adenosine signalling activators. *British Journal of Pharmacology*, **2021**, 178, 4758-4771	8.6	1
243	A novel genetic variant in PTGS1 affects N-glycosylation of cyclooxygenase-1 causing a dominant-negative effect on platelet function and bleeding diathesis. *American Journal of Hematology*, **2021**, 96, E83-E88	7.1	1
242	Platelet Reactivity in Individuals Over 65 Years Old Is Not Modulated by Age. *Circulation Research*, **2020**, 127, 394-396	15.7	1
241	Loss of GPVI and GPIbβ contributes to trauma-induced platelet dysfunction in severely injured patients. *Blood Advances*, **2020**, 4, 2623-2630	7.8	7
240	Combination of cyclic nucleotide modulators with P2Y receptor antagonists as anti-platelet therapy. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 1705-1713	15.4	3
239	Hypoxia Modulates Platelet Purinergic Signalling Pathways. *Thrombosis and Haemostasis*, **2020**, 120, 253-261	7	5
238	Profiling the eicosanoid networks that underlie the anti- and pro-thrombotic effects of aspirin. *FASEB Journal*, **2020**, 34, 10027-10040	0.9	5
237	Cell-Specific Gene Deletion Reveals the Antithrombotic Function of COX1 and Explains the Vascular COX1/Prostacyclin Paradox. *Circulation Research*, **2019**, 125, 847-854	15.7	14
236	Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy. *Pharmacology & Therapeutics*, **2019**, 193, 83-90	13.9	9
235	Histone H4 induces platelet ballooning and microparticle release during trauma hemorrhage. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 17444-17449	11.5	35
234	Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. *Journal of Clinical Investigation*, **2019**, 129, 1845-1862	15.9	76
233	Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond). *British Journal of Pharmacology*, **2019**, 176, 988-999	8.6	33
232	Kidney Transplantation in a Patient Lacking Cytosolic Phospholipase A Proves Renal Origins of Urinary PGI-M and TX-M. *Circulation Research*, **2018**, 122, 555-559	15.7	19

231	Platelet responses to pharmacological and physiological interventions in middle-aged men with different habitual physical activity levels. *Acta Physiologica*, **2018**, 223, e13028	5.6	7
230	Not all light transmission aggregation assays are created equal: qualitative differences between light transmission and 96-well plate aggregometry. *Platelets*, **2018**, 29, 686-689	3.6	9
229	96-well plate-based aggregometry. *Platelets*, **2018**, 29, 650-655	3.6	12
228	Platelet reactivity influences clot structure as assessed by fractal analysis of viscoelastic properties. *Platelets*, **2018**, 29, 162-170	3.6	3
227	Inhibition of profibrotic microRNA-21 affects platelets and their releasate. *JCI Insight*, **2018**, 3,	9.9	16
226	Understanding the cardiovascular effects of low dose aspirin by using a platelet COX-1-/- mouse model. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, PO4-2-57	0	
225	Platelet reactivity in an elderly and healthy population. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, OR25-2	0	
224	In celebration of Professor Gus Born's life, 29 July 1921 - 16 April 2018. *Platelets*, **2018**, 29, 743	3.6	
223	Letter by Mitchell et al Regarding Article, "Urinary Prostaglandin Metabolites: An Incomplete Reckoning and a Flush to Judgment". *Circulation Research*, **2018**, 122, e84-e85	15.7	2
222	Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, 949-956	9.4	45
221	Pharmacological assessment of ibuprofen arginate on platelet aggregation and colon cancer cell killing. *Biochemical and Biophysical Research Communications*, **2017**, 484, 762-766	3.4	8
220	Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, 1482-1493	9.4	15
219	Inhibition of platelet aggregation ex vivo is repressed in apolipoprotein E deficient mice. *Canadian Journal of Physiology and Pharmacology*, **2017**, 95, 954-960	2.4	
218	Aspirin inhibits the production of proangiogenic 15(S)-HETE by platelet cyclooxygenase-1. *FASEB Journal*, **2016**, 30, 4256-4266	0.9	35
217	Association of MicroRNAs and YRNAs With Platelet Function. *Circulation Research*, **2016**, 118, 420-432	15.7	125
216	P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation. *British Journal of Clinical Pharmacology*, **2016**, 81, 621-33	3.8	21
215	Human Platelets Utilize Cycloxygenase-1 to Generate Dioxolane A3, a Neutrophil-activating Eicosanoid. *Journal of Biological Chemistry*, **2016**, 291, 13448-64	5.4	13
214	Protocol for a human in vivo model of acute cigarette smoke inhalation challenge in smokers with COPD: monitoring the nasal and systemic immune response using a network biology approach. *BMJ Open*, **2015**, 5, e005750	3	1

213	Reply to letter regarding article, "evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs". *Circulation*, **2015**, 132, e213-4	16.7	2
212	Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography. *Platelets*, **2015**, 26, 689-92	3.6	9
211	Inherited human group IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation. *FASEB Journal*, **2015**, 29, 4568-78	0.9	20
210	Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. *Circulation*, **2015**, 131, 633-42	16.7	60
209	Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interaction. *Blood*, **2015**, 126, e11-8	2.2	20
208	Expression of the PlA2 allele of glycoprotein IIIa and its impact on platelet function. *JRSM Cardiovascular Disease*, **2015**, 4, 2048004015610252	1.1	1
207	Effects of high flavanol dark chocolate on cardiovascular function and platelet aggregation. *Vascular Pharmacology*, **2015**, 71, 70-8	5.9	28
206	Drug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet Therapy. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 2122-33	9.4	13
205	Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay. *Blood*, **2014**, 123, e11-22	2.2	50
204	COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks. *PLoS ONE*, **2014**, 9, e98165	3.7	39
203	Cryptogenic multifocal ulcerating stenosing enteritis associated with homozygous deletion mutations in cytosolic phospholipase A2-. *Gut*, **2014**, 63, 96-104	19.2	45
202	Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 15812-7	11.5	49
201	High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition. *Thrombosis Research*, **2013**, 131, 313-9	8.2	13
200	Differential COX-2 induction by viral and bacterial PAMPs: Consequences for cytokine and interferon responses and implications for anti-viral COX-2 directed therapies. *Biochemical and Biophysical Research Communications*, **2013**, 438, 249-56	3.4	30
199	Circulating microRNAs as novel biomarkers for platelet activation. *Circulation Research*, **2013**, 112, 595-600	10.7	285
198	265 PLASMA MICRORNAS AS BIOMARKERS FOR PLATELET INHIBITION. *Heart*, **2013**, 99, A139.3-A140	5.1	1
197	Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 15782-7	11.5	43
196	Aspirin-triggered 15-epi-lipoxin A4 predicts cyclooxygenase-2 in the lungs of LPS-treated mice but not in the circulation: implications for a clinical test. *FASEB Journal*, **2013**, 27, 3938-46	0.9	14

195	Reply to Ricciotti et al.: Evidence for vascular COX isoforms. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E184	11.5	4
194	207 PLATELET COX-1 SUPPORTS THE PRODUCTION OF BOTH PROSTANOIDS AND HETES. *Heart*, **2013**, 99, A114.1-A114	5.1	
193	236 DURING ANTI-PLATELET THERAPY PLATELET TURNOVER MAY LEAD TO THE EMERGENCE OF A MINORITY OF UNINHIBITED PLATELETS SUFFICIENT TO INITIATE AND DRIVE PLATELET AGGREGATE FORMATION. *Heart*, **2013**, 99, A126.2-A127	5.1	
192	261 P2Y12 INHIBITION GREATLY POTENTIATES THE ANTI-PLATELET EFFECTS OF PROSTACYCLIN AND NITRIC OXIDE. *Heart*, **2013**, 99, A137.2-A138	5.1	1
191	LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression. *PLoS ONE*, **2013**, 8, e69524	3.7	47
190	Cox2 reporter gene expression and prostacylin mass spectrometry confirm vascular COX-1 dominance for prostacyclin production. *FASEB Journal*, **2013**, 27, lb507	0.9	
189	Standardised optical multichannel (optimul) platelet aggregometry using high-speed shaking and fixed time point readings. *Platelets*, **2012**, 23, 404-8	3.6	24
188	Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 17597-602	11.5	87
187	Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress. *Cardiovascular Research*, **2012**, 93, 674-81	9.9	39
186	Evaluation of the Pharmacodynamics of Acetylsalicylic Acid 81 mg With or Without Esomeprazole 20 mg in Healthy Volunteers. *American Journal of Cardiovascular Drugs*, **2012**, 12, 217-224	4	10
185	Optical multichannel (optimul) platelet aggregometry in 96-well plates as an additional method of platelet reactivity testing. *Platelets*, **2011**, 22, 485-94	3.6	42
184	Clopidogrel withdrawal: is there a "rebound" phenomenon?. *Thrombosis and Haemostasis*, **2011**, 105, 211-20	7	49
183	Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse. *PLoS ONE*, **2011**, 6, e20062	3.7	30
182	Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. *British Journal of Clinical Pharmacology*, **2011**, 72, 619-33	3.8	135
181	In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 552-61	15.4	119
180	Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 2050-6	15.4	25
179	Antiplatelet effects of aspirin vary with level of P2Y receptor blockade supplied by either ticagrelor or prasugrel. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 2103-5	15.4	54
178	4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor. *Oncogene*, **2011**, 30, 106-16	9.2	42

177	Gasotransmitters and platelets. *Pharmacology & Therapeutics*, **2011**, 132, 196-203	13.9	22
176	46 Urinary prostanoid metabolites in healthy volunteers taking prasugrel and aspirin. *Heart*, **2011**, 97, e7-e7	5.1	
175	12 Relationship between proportions of P2Y12 inhibited platelets and aggregation in vitro. *Heart*, **2011**, 97, e7-e7	5.1	
174	Role of shear stress in endothelial cell morphology and expression of cyclooxygenase isoforms. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 384-91	9.4	60
173	Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. *Heart*, **2011**, 97, 1661-7	5.1	27
172	Endogenous epoxygenases are modulators of monocyte/macrophage activity. *PLoS ONE*, **2011**, 6, e26593	3.7	62
171	22 Inhibition Of ADP- and thromboxane-dependent pathways of platelet aggregation by The P2Y12 antagonists, ticagrelor and prasugrel. *Heart*, **2011**, 97, e7-e7	5.1	
170	Nucleotide oligomerization domain 1 is a dominant pathway for NOS2 induction in vascular smooth muscle cells: comparison with Toll-like receptor 4 responses in macrophages. *British Journal of Pharmacology*, **2010**, 160, 1997-2007	8.6	21
169	Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?. *Heart*, **2010**, 96, 1693-4	5.1	33
168	Trapping of palindromic ligands within native transthyretin prevents amyloid formation. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 20483-8	11.5	50
167	Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 613-5	15.4	56
166	Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness. *Thrombosis and Haemostasis*, **2009**, 102, 772-8	7	35
165	The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo. *PLoS ONE*, **2009**, 4, e7421	3.7	47
164	Antiplatelet actions of statins and fibrates are mediated by PPARs. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 706-11	9.4	95
163	Effects of low-dose aspirin on acute inflammatory responses in humans. *Journal of Immunology*, **2009**, 183, 2089-96	5.3	228
162	PPARbeta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKCalpha--brief report. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 1871-3	9.4	39
161	Inhibition of thromboxane synthase induces lung cancer cell death via increasing the nuclear p27. *Experimental Cell Research*, **2009**, 315, 2974-81	4.2	15
160	Rapid and accurate method for the von Willebrand factor ristocetin cofactor assay using 96-well microtiter plates. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 1226-8	15.4	2

159	Heparin but not citrate anticoagulation of blood preserves platelet function for prolonged periods. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 1897-905	15.4	20
158	Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. *Journal of Thrombosis and Haemostasis*, **2008**, 6, 1933-43	15.4	57
157	COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. *Lancet, The*, **2008**, 371, 270-3	40	123
156	COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma. *FASEB Journal*, **2008**, 22, 4005-10	0.9	46
155	Interleukin-1beta, but not interleukin-6, enhances renal and systemic endothelin production in vivo. *American Journal of Physiology - Renal Physiology*, **2008**, 295, F446-53	4.3	33
154	Identification and characterization of a dysfunctional cardiac myocyte phenotype: role of bacteria, Toll-like receptors, and endothelin. *Shock*, **2007**, 28, 434-40	3.4	6
153	Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 63-9	9.4	201
152	Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. *Blood*, **2007**, 109, 3741-4	2.2	69
151	Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 2606-11	9.4	124
150	Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. *American Journal of Respiratory Cell and Molecular Biology*, **2006**, 34, 242-6	5.7	75
149	The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. *Cancer Research*, **2006**, 66, 10120-6	10.1	139
148	Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2. *FASEB Journal*, **2006**, 20, 542-4	0.9	38
147	The effect of NCX4016 [2-acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl ester] on the consequences of ischemia and reperfusion in the streptozotocin diabetic rat. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 316, 1107-14	4.7	9
146	Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. *FASEB Journal*, **2006**, 20, 326-8	0.9	96
145	Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. *FASEB Journal*, **2006**, 20, 2468-75	0.9	60
144	COX-2 in cardiovascular disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 956-8	9.4	46
143	The flavonoid quercetin induces apoptosis and inhibits JNK activation in intimal vascular smooth muscle cells. *Biochemical and Biophysical Research Communications*, **2006**, 346, 919-25	3.4	68
142	Increased thromboxane B(2) levels are associated with lipid peroxidation and Bcl-2 expression in human lung carcinoma. *Cancer Letters*, **2006**, 234, 193-8	9.9	20

141	COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. *Nature Reviews Drug Discovery*, **2006**, 5, 75-86	64.1	196
140	Discontinuation of Vioxx. *Lancet, The*, **2005**, 365, 27-28	40	2
139	NSAIDs increase GM-CSF release by human synoviocytes: comparison with nitric oxide-donating derivatives. *European Journal of Pharmacology*, **2005**, 508, 7-13	5.3	5
138	Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. *Journal of Cellular Biochemistry*, **2005**, 96, 760-74	4.7	59
137	Role of Toll-like receptors 2 and 4 in the induction of cyclooxygenase-2 in vascular smooth muscle. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 4637-42	11.5	53
136	Cellular mechanisms of acetaminophen: role of cyclo-oxygenase. *FASEB Journal*, **2005**, 19, 635-7	0.9	94
135	The molecular and biological basis for COX-2 selectivity **2004**, 41-65		
134	Cyclooxygenases 1, 2, and 3 and the production of prostaglandin I2: investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 310, 642-7	4.7	40
133	Expression and activation of the farnesoid X receptor in the vasculature. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 3668-73	11.5	172
132	Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. *FASEB Journal*, **2004**, 18, 790-804	0.9	482
131	Role for nuclear factor-kappaB and signal transducer and activator of transcription 1/interferon regulatory factor-1 in cytokine-induced endothelin-1 release in human vascular smooth muscle cells. *Molecular Pharmacology*, **2003**, 64, 923-31	4.3	55
130	HIF, stretching to get control of VEGF. *Clinical Science*, **2003**, 105, 393-4	6.5	8
129	Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: as easy as ABC?. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 9108-10	11.5	16
128	PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist. *FASEB Journal*, **2003**, 17, 1925-7	0.9	61
127	Effects of cyclooxygenase-1/cyclooxygenase-2 inhibition on leukocyte/endothelial cell interactions in the rat mesentery. *European Journal of Pharmacology*, **2002**, 440, 71-7	5.3	1
126	Placentally derived prostaglandin E2 acts via the EP4 receptor to inhibit IL-2-dependent proliferation of CTLL-2 T cells. *Clinical and Experimental Immunology*, **2002**, 127, 263-9	6.2	36
125	Modulation of colony stimulating factor release and apoptosis in human colon cancer cells by anticancer drugs. *British Journal of Cancer*, **2002**, 86, 1316-21	8.7	10
124	Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors. *British Journal of Pharmacology*, **2002**, 137, 1031-8	8.6	41

123	Endothelin content, expression, and receptor type in normal and diseased human gallbladder. *Digestive Diseases and Sciences*, **2002**, 47, 1786-92	4	3
122	Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy. *Circulation Research*, **2002**, 91, 210-7	15.7	55
121	Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 13371-3	11.5	205
120	Cyclooxygenase-2 acts as an endogenous brake on endothelin-1 release by human pulmonary artery smooth muscle cells: implications for pulmonary hypertension. *Molecular Pharmacology*, **2002**, 62, 1147-53	4.3	26
119	Origins of prostaglandin E2: involvements of cyclooxygenase (COX)-1 and COX-2 in human and rat systems. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 303, 1001-6	4.7	82
118	Modulation by colony stimulating factors of human epithelial colon cancer cell apoptosis. *Cytokine*, **2002**, 20, 163-7	4	18
117	Cyclo-oxygenase-2 inhibitors and cardiovascular events. *Lancet, The*, **2002**, 360, 1700-1	40	6
116	Endothelin in human inflammatory bowel disease: comparison to rat trinitrobenzenesulphonic acid-induced colitis. *Life Sciences*, **2002**, 71, 1893-904	6.8	22
115	Synthesis of substituted benzamides as anti-inflammatory agents that inhibit preferentially cyclooxygenase 1 but do not cause gastric damage. *European Journal of Medicinal Chemistry*, **2001**, 36, 517-30	6.8	24
114	Relationship between endogenous colony stimulating factors and apoptosis in human colon cancer cells: role of cyclo-oxygenase inhibitors. *British Journal of Pharmacology*, **2001**, 134, 1237-44	8.6	12
113	Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. *European Journal of Pharmacology*, **2001**, 426, 95-103	5.3	24
112	Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. *Thorax*, **2001**, 56, 30-5	7.3	118
111	Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling. *American Journal of Respiratory Cell and Molecular Biology*, **2001**, 25, 104-10	5.7	73
110	Sodium salicylate inhibits prostaglandin formation without affecting the induction of cyclooxygenase-2 by bacterial lipopolysaccharide in vivo. *Journal of Pharmacology and Experimental Therapeutics*, **2001**, 299, 894-900	4.7	12
109	Signal transduction pathways involved in cytokine stimulation of endothelin-1 release from human vascular smooth muscle cells. *Journal of Cardiovascular Pharmacology*, **2000**, 36, S407-9	3.1	15
108	Bisphenol A diglycidyl ether (BADGE) is a PPARgamma agonist in an ECV304 cell line. *British Journal of Pharmacology*, **2000**, 131, 651-4	8.6	50
107	Effects of nitric oxide-modulating amino acids on coronary vessels: relevance to sepsis. *European Journal of Pharmacology*, **2000**, 389, 209-15	5.3	13
106	Cyclic AMP regulates cytokine stimulation of endothelin-1 release in human vascular smooth muscle cells. *Journal of Cardiovascular Pharmacology*, **2000**, 36, S404-6	3.1	5

105	Signal Transduction Pathways Involved in Cytokine Stimulation of Endothelin-1 Release from Human Vascular Smooth Muscle Cells. *Journal of Cardiovascular Pharmacology*, **2000**, 36, S407-S409	3.1	3
104	The prostacyclin-mimetic cicaprost inhibits endogenous endothelin-1 release from human pulmonary artery smooth muscle cells. *Journal of Cardiovascular Pharmacology*, **2000**, 36, S410-3	3.1	26
103	Nomenclature for COX-2 inhibitors. *Lancet, The*, **2000**, 356, 1373-4	40	40
102	Regulation of iNOS mRNA levels in endothelial cells by glutathione, a double-edged sword. *Free Radical Research*, **2000**, 32, 223-34	4	23
101	Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal antiinflammatory drug efficacy. *FASEB Journal*, **1999**, 13, 245-51	0.9	41
100	Selective COX-2 inhibitors and human inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **1999**, 13, 1115-7	6.1	55
99	Relationships between the endothelin and nitric oxide pathways. *Clinical and Experimental Pharmacology and Physiology*, **1999**, 26, 247-52	3	54
98	Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. *British Journal of Pharmacology*, **1999**, 126, 1824-30	8.6	67
97	A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. *British Journal of Pharmacology*, **1999**, 127, 1589-96	8.6	59
96	Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. *British Journal of Pharmacology*, **1999**, 128, 1121-32	8.6	202
95	Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 7563-8	11.5	1251
94	Expression of cyclooxygenase-2 in rat vascular smooth muscle cells is unrelated to nuclear factor-kappaB activation. *Life Sciences*, **1999**, 64, 1231-42	6.8	29
93	Endothelin Receptors and Ligands **1999**, 21-48		
92	Nitric oxide and endothelin-1 in circulatory shock involving cytokines **1999**, 151-171		
91	Mechanisms of prostaglandin E2 release by intact cells expressing cyclooxygenase-2: evidence for a Qwo-componentQmodel. *Journal of Pharmacology and Experimental Therapeutics*, **1999**, 288, 1101-6	4.7	21
90	Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. *Molecular Pharmacology*, **1999**, 55, 902-9	4.3	90
89	Interactions between inducible isoforms of nitric oxide synthase and cyclo-oxygenase in vivo: investigations using the selective inhibitors, 1400W and celecoxib. *British Journal of Pharmacology*, **1998**, 125, 335-40	8.6	44
88	Role of AT2 receptors in the cardiovascular events following microinjection of angiotensin II into the superior colliculus of anaesthetised rats. *Naunyn-Schmiedebergls Archives of Pharmacology*, **1998**, 357, 121-5	3.4	6

87	Regulation of cyclo-oxygenase gene expression in rat smooth muscle cells by catalase. *Biochemical Pharmacology*, **1998**, 55, 1621-31	6	34
86	NOS inhibitors in colitis: a suitable case for treatment?. *Gut*, **1998**, 42, 152-3	19.2	3
85	Cytokine and lipopolysaccharide stimulation of endothelin-1 release from human internal mammary artery and saphenous vein smooth-muscle cells. *Journal of Cardiovascular Pharmacology*, **1998**, 31 Suppl 1, S348-50	3.1	32
84	Cytokine Regulation of Endothelin Action **1998**, 89-100		
83	The Development of Specific Endothelin-Receptor Antagonists **1998**, 189-222		
82	Shock news for the gut. *Gut*, **1998**, 42, 606	19.2	
81	Contraction of human airway smooth muscle by endothelin-1 and IRL 1620: effect of bosentan. *European Journal of Pharmacology*, **1997**, 324, 219-22	5.3	18
80	Regulation of blood pressure by L-arginine-nitric oxide pathway within the superior colliculus of rats. *European Journal of Pharmacology*, **1997**, 328, 65-7	5.3	2
79	Activation of ET(A) receptors is partially responsible for the rapid increase in haematocrit induced by bacterial lipopolysaccharide in the rat. *Life Sciences*, **1997**, 60, PL 271-6	6.8	2
78	Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture. *British Journal of Pharmacology*, **1997**, 121, 125-33	8.6	81
77	A single competitive reverse transcriptase-polymerase chain reaction assay to measure inducible nitric oxide synthase gene expression in both human and rat. *Analytical Biochemistry*, **1997**, 247, 455-8	3.1	2
76	Endothelin-1 and the periaqueductal gray area of the rat: an autoradiographic and functional pharmacological study. *British Journal of Pharmacology*, **1996**, 118, 21-6	8.6	7
75	Cardiovascular responses induced by injection of endothelin-1 into the superior colliculus of rats. *European Journal of Pharmacology*, **1996**, 316, 245-7	5.3	5
74	What turns on the endothelins?. *Inflammation Research*, **1996**, 45, 51-3	7.2	32
73	Influence of endothelial mediators on the vascular smooth muscle and circulating platelets and blood cells. *International Angiology*, **1996**, 15, 93-9	2.2	12
72	NG-Hydroxy-L-Arginine Releases from Endothelial Cells Nitric Oxide which Increases cGMP in RFL-6 Fibroblasts. *Endothelium: Journal of Endothelial Cell Research*, **1995**, 3, 121-129		1
71	Endothelin 1 mediates ex vivo coronary vasoconstriction caused by exogenous and endogenous cytokines. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 2691-5	11.5	75
70	Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat: use of selective antagonists. *British Journal of Pharmacology*, **1995**, 116, 2482-6	8.6	32

69	The contribution of tumour necrosis factor-alpha and endothelin-1 to the increase of coronary resistance in hearts from rats treated with endotoxin. *British Journal of Pharmacology*, **1995**, 116, 3309-15	8.6	43
68	Involvement of endothelin in the pressor response following injection of NMDA to the periaqueductal gray area of rats. *British Journal of Pharmacology*, **1995**, 116, 2787-9	8.6	6
67	Rapid degradation of endothelin-1 by an enzyme released by the rat isolated perfused mesentery. *British Journal of Pharmacology*, **1995**, 114, 867-71	8.6	8
66	Coronary vasoconstriction in vitro in the hearts of polyarthritic rats: effectiveness of in vivo treatment with the endothelin receptor antagonist SB 209670. *British Journal of Pharmacology*, **1995**, 114, 1327-8	8.6	3
65	Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. *British Journal of Pharmacology*, **1995**, 114, 1335-42	8.6	260
64	Contractile activity of endothelin precursors in the isolated gallbladder of the guinea-pig: presence of an endothelin-converting enzyme. *British Journal of Pharmacology*, **1995**, 114, 1383-90	8.6	4
63	Comparison of effects of chronic and acute administration of NG-nitro-L-arginine methyl ester to the rat on inhibition of nitric oxide-mediated responses. *British Journal of Pharmacology*, **1995**, 114, 1673-9	8.6	42
62	Characterization of receptors for kinins and neurokinins in the arterial and venous mesenteric vasculatures of the guinea-pig. *British Journal of Pharmacology*, **1995**, 115, 1319-25	8.6	25
61	Characterization of endothelin receptors mediating mechanical responses to the endothelins in the isolated stomach strip of the rat. *Journal of Pharmacology and Experimental Therapeutics*, **1995**, 275, 120-6	4.7	10
60	Inhibition of ETB Receptors Limits the Efficacy of Nonselective Endothelin Antagonists In Vivo. *Journal of Cardiovascular Pharmacology*, **1995**, 26, S177-179	3.1	11
59	Endothelin-1 Mediates Coronary Vasoconstriction Caused by Exogenous and Endogenous Cytokines. *Journal of Cardiovascular Pharmacology*, **1995**, 26, S419-421	3.1	13
58	Endothelins: Recent Progress **1995**, 313-318		
57	Endothelin Receptor Antagonists. *Cardiovascular Drug Reviews*, **1994**, 12, 105-122		32
56	Synthesis and biological activity of the novel nitric oxide synthase inhibitor N□-hydroxy-N□-methyl-L-arginine. *Journal of the Chemical Society Perkin Transactions 1*, **1994**, 769-771		13
55	Endothelin-1 release from endothelial cells in culture is elevated both acutely and chronically by short periods of mechanical stretch. *Biochemical and Biophysical Research Communications*, **1994**, 200, 395-400	3.4	134
54	Endothelin receptor antagonists: actions and rationale for their development. *Biochemical Pharmacology*, **1994**, 48, 625-35	6	39
53	Comparison of PD 145065 and Ro 46-2005 as antagonists of contractions of guinea-pig airways induced by endothelin-1 or IRL 1620. *European Journal of Pharmacology*, **1994**, 252, 341-5	5.3	11
52	Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. *British Journal of Pharmacology*, **1994**, 112, 207-13	8.6	52

51	The effect of nitric oxide synthase inhibition on the plasma fibrinolytic system in septic shock in rats. *British Journal of Pharmacology*, **1994**, 112, 289-91	8.6	17
50	Characterization of endothelin (ET) receptors in the isolated gall bladder of the guinea-pig: evidence for an additional ET receptor subtype. *British Journal of Pharmacology*, **1994**, 112, 1244-50	8.6	27
49	5-HT3 receptors do not mediate vagally-induced relaxation or contraction of the isolated stomach of the guinea-pig. *British Journal of Pharmacology*, **1994**, 111, 346-50	8.6	4
48	Evidence from receptor antagonists of an important role for ETB receptor-mediated vasoconstrictor effects of endothelin-1 in the rat kidney. *British Journal of Pharmacology*, **1994**, 111, 515-20	8.6	57
47	Characterization of ETB receptors mediating contractions induced by endothelin-1 or IRL 1620 in guinea-pig isolated airways: effects of BQ-123, FR139317 or PD 145065. *British Journal of Pharmacology*, **1994**, 111, 1009-16	8.6	47
46	Nitric oxide, and not vasoactive intestinal peptide, as the main neurotransmitter of vagally induced relaxation of the guinea pig stomach. *British Journal of Pharmacology*, **1994**, 113, 1197-202	8.6	46
45	Effects of cyclic GMP on smooth muscle relaxation. *Advances in Pharmacology*, **1994**, 26, 171-94	5.7	88
44	Relationship between different isoforms of nitric oxide synthase and cyclooxygenase in various cell types. *Polish Journal of Pharmacology*, **1994**, 46, 587-92		5
43	Endothelin ETA and ETB receptors mediate vasoconstriction and prostanoid release in the isolated kidney of the rat. *European Journal of Pharmacology*, **1993**, 250, 447-53	5.3	34
42	Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. *British Journal of Pharmacology*, **1993**, 108, 776-9	8.6	111
41	Induction by endotoxin of nitric oxide synthase in the rat mesentery: lack of effect on action of vasoconstrictors. *British Journal of Pharmacology*, **1993**, 109, 265-70	8.6	106
40	Characterization of receptors for endothelins in the perfused arterial and venous mesenteric vasculatures of the rat. *British Journal of Pharmacology*, **1993**, 110, 687-92	8.6	38
39	Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. *British Journal of Pharmacology*, **1993**, 110, 777-82	8.6	148
38	Characterization of endothelin receptors mediating the effects of the endothelin/sarafotoxin peptides on autonomic neurotransmission in the rat vas deferens and guinea-pig ileum. *British Journal of Pharmacology*, **1993**, 110, 783-9	8.6	32
37	The metabolism of endothelin-1 and big endothelin-1 by the isolated perfused kidney of the rabbit. *Journal of Cardiovascular Pharmacology*, **1993**, 22 Suppl 8, S65-8	3.1	2
36	Comparative studies with the endothelin receptor antagonists BQ-123 and PD 142893 indicate at least three endothelin receptors. *Journal of Cardiovascular Pharmacology*, **1993**, 22 Suppl 8, S117-20	3.1	45
35	Vasoconstriction in the rat kidney induced by endothelin-1 is blocked by PD 145065. *Journal of Cardiovascular Pharmacology*, **1993**, 22 Suppl 8, S103-6	3.1	15
34	Characterization of endothelin synthetic pathways and receptor subtypes: physiological and pathophysiological implications. *European Heart Journal*, **1993**, 14 Suppl I, 42-7	9.5	3

33	Characterization of serine protease-derived metabolites of big endothelin in the cytosolic fraction from human polymorphonuclear leukocytes. *Journal of Cardiovascular Pharmacology*, **1992**, 20 Suppl 12, S22-4	3.1	11
32	Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen oxides. *Science*, **1992** , 255, 721-3	33.3	380
31	Detection by bioassay and specific enzyme-linked immunosorbent assay of phosphoramidon-inhibitable endothelin-converting activity in brain and endothelium. *Journal of Cardiovascular Pharmacology*, **1992**, 20 Suppl 12, S19-21	3.1	7
30	Different patterns of release of endothelium-derived relaxing factor and prostacyclin. *British Journal of Pharmacology*, **1992**, 105, 485-9	8.6	28
29	Human brain contains a metalloprotease that converts big endothelin-1 to endothelin-1 and is inhibited by phosphoramidon and EDTA. *British Journal of Pharmacology*, **1992**, 106, 505-6	8.6	12
28	Regional differences in endothelin converting enzyme activity in rat brain: inhibition by phosphoramidon and EDTA. *British Journal of Pharmacology*, **1992**, 106, 948-52	8.6	24
27	Nitric oxide synthase in ferret brain: localization and characterization. *British Journal of Pharmacology*, **1992**, 107, 849-52	8.6	9
26	Double-edged role of endogenous nitric oxide. *Lancet, The*, **1992**, 339, 986	40	20
25	Bioassay for EDRF/NO by accumulation of cyclic GMP in RFL-6 fetal rat lung fibroblasts. *Methods*, **1992**, 1, 117-123		1
24	Interactions of endothelins and EDRF in bovine native endothelial cells: selective effects of endothelin-3. *American Journal of Physiology - Heart and Circulatory Physiology*, **1992**, 262, H1600-5	5.2	9
23	Characterization of endothelin-converting enzyme from endothelial cells and rat brain: detection of the formation of biologically active endothelin-1 by rapid bioassay. *Molecular Pharmacology*, **1992**, 41, 399-403	4.3	12
22	Regulation and subcellular location of nitrogen oxide synthases in RAW264.7 macrophages. *Molecular Pharmacology*, **1992**, 41, 615-24	4.3	194
21	Induction of NADPH-dependent diaphorase and nitric oxide synthase activity in aortic smooth muscle and cultured macrophages. *Molecular Pharmacology*, **1992**, 41, 1163-8	4.3	35
20	Response : Nitric Oxide and Arginine-Evoked Insulin Secretion. *Science*, **1992**, 258, 1376-1378	33.3	
19	Response : Nitric Oxide and Arginine-Evoked Insulin Secretion. *Science*, **1992**, 258, 1376-1378	33.3	3
18	Human big endothelin releases prostacyclin in vivo and in vitro through a phosphoramidon-sensitive conversion to endothelin-1. *Journal of Cardiovascular Pharmacology*, **1991**, 17 Suppl 7, S251-5	3.1	21
17	Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. *Proceedings of the National Academy of Sciences of the United States of America*, **1991**, 88, 10480-4	11.5	822
16	Endothelin-1 stimulates cyclic GMP formation in porcine kidney epithelial cells via activation of the L-arginine-dependent soluble guanylate cyclase pathway. *Journal of Cardiovascular Pharmacology*, **1991**, 17 Suppl 7, S246-50	3.1	6

15	Alkaline buffers release EDRF from bovine cultured aortic endothelial cells. *British Journal of Pharmacology*, **1991**, 103, 1295-302	8.6	18
14	Endothelial cells have a particulate enzyme system responsible for EDRF formation: measurement by vascular relaxation. *Biochemical and Biophysical Research Communications*, **1991**, 176, 1417-23	3.4	40
13	Neurokinins produce selective venoconstriction via NK-3 receptors in the rat mesenteric vascular bed. *European Journal of Pharmacology*, **1991**, 204, 329-34	5.3	51
12	Isoforms of nitric oxide synthase. Characterization and purification from different cell types. *Biochemical Pharmacology*, **1991**, 42, 1849-57	6	759
11	A simple and sensitive bioassay method for detection of EDRF with RFL-6 rat lung fibroblasts. *American Journal of Physiology - Heart and Circulatory Physiology*, **1991**, 261, H598-603	5.2	33
10	Endothelin increases cyclic GMP levels in LLC-PK1 porcine kidney epithelial cells via formation of an endothelium-derived relaxing factor-like substance. *Journal of Pharmacology and Experimental Therapeutics*, **1991**, 259, 1102-8	4.7	25
9	Intravascular big endothelin increases circulating levels of endothelin-1 and prostanoids in the rabbit. *Biochemical Pharmacology*, **1990**, 39, R21-2	6	49
8	Endothelin-1 and U46619 potentiate selectively the venous responses to nerve stimulation within the perfused superior mesenteric vascular bed of the rat. *Biochemical and Biophysical Research Communications*, **1990**, 172, 745-50	3.4	8
7	Simultaneous perfusion of rat isolated superior mesenteric arterial and venous beds: comparison of their vasoconstrictor and vasodilator responses to agonists. *British Journal of Pharmacology*, **1990**, 99, 427-33	8.6	63
6	Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. *Journal of Cardiovascular Pharmacology*, **1989**, 13 Suppl 5, S85-8; discussion S102	3.1	245
5	Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. *European Journal of Pharmacology*, **1989**, 159, 325-6	5.3	225
4	Comparison of the survival of endothelium-derived relaxing factor and nitric oxide within the isolated perfused mesenteric arterial bed of the rat. *British Journal of Pharmacology*, **1989**, 97, 777-82	8.6	7
3	Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. *Proceedings of the National Academy of Sciences of the United States of America*, **1988**, 85, 9797-800	11.5	1144
2	Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. *Proceedings of the National Academy of Sciences of the United States of America*, **1988**, 85, 2334-8	11.5	224
1	Proteome and functional decline as platelets age in the circulation		1